

Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma

Eugene J. Vaios¹, Kristen A. Batich², Anne F. Buckley³, Anastasie Dunn-Pirio⁴, Mallika P. Patel⁵, John P. Kirkpatrick¹, Ranjit Goudar⁶ and Katherine B. Peters^{7,8}

¹Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA

²Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

³Department of Pathology, Duke University Medical Center, Durham, NC, USA

⁴Department of Neurology, UC San Diego Health, San Diego, CA, USA

⁵Department of Pharmacy, Duke University Medical Center, Durham, NC, USA

⁶Virginia Oncology Associates, Norfolk, VA, USA

⁷Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA

⁸Department of Neurology, Duke University Medical Center, Durham, NC, USA

Published: October 20, 2022

Copyright: © 2022 Vaios et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: Informed consent was obtained from each patient and the study was approved by our institution.

Original article: Oncotarget. 2022; 13:576–582. <https://doi.org/10.18632/oncotarget.28222>